ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc

Bullboard Posts

Post by jjwilsonon May 28, 2010 11:53am

302 Views

Post# 17140201

Again - no reaction to good news.

I've been a shareholder for several years and have just recently added to my share count. I've just got to comment on the lack of activity to the the latest couple of NRs. It seems odd to me that there is no response to what sounds to me like good news. Why is this? Either I'm wrong or the market is wrong and by my previous experience, it's usually me that has played it wrong. Has Amorfix fallen so far off the RADAR that it's invisible?

Bullboard Posts

Investor’s corner: Solving chronic pain in dogs – A significant market opportunity